Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,503 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 15th. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85. Following the transaction, the insider now owns 164,363 shares in the company, valued at approximately $2,292,863.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The stock was sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Trading Down 2.0 %

Hims & Hers Health stock traded down $0.26 during mid-day trading on Wednesday, reaching $12.43. The company’s stock had a trading volume of 2,231,076 shares, compared to its average volume of 4,688,743. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -114.55 and a beta of 0.91. The business has a 50 day moving average price of $13.36 and a 200-day moving average price of $9.77. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The company’s revenue for the quarter was up 47.4% compared to the same quarter last year. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently bought and sold shares of HIMS. CM Wealth Advisors LLC acquired a new stake in Hims & Hers Health in the second quarter worth about $25,000. Point72 Middle East FZE acquired a new stake in Hims & Hers Health in the fourth quarter worth about $29,000. Captrust Financial Advisors raised its position in Hims & Hers Health by 1,827.4% in the first quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after acquiring an additional 6,414 shares in the last quarter. Harbour Investments Inc. raised its position in Hims & Hers Health by 427.9% in the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after acquiring an additional 5,670 shares in the last quarter. Finally, Belpointe Asset Management LLC bought a new stake in Hims & Hers Health in the first quarter worth about $46,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on HIMS. SVB Leerink began coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They issued a “market perform” rating and a $10.00 target price on the stock. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Guggenheim boosted their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Citigroup boosted their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.